Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15683753rdf:typepubmed:Citationlld:pubmed
pubmed-article:15683753lifeskim:mentionsumls-concept:C0020792lld:lifeskim
pubmed-article:15683753lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:15683753lifeskim:mentionsumls-concept:C0040615lld:lifeskim
pubmed-article:15683753lifeskim:mentionsumls-concept:C1442161lld:lifeskim
pubmed-article:15683753lifeskim:mentionsumls-concept:C1335671lld:lifeskim
pubmed-article:15683753lifeskim:mentionsumls-concept:C2003941lld:lifeskim
pubmed-article:15683753lifeskim:mentionsumls-concept:C1516691lld:lifeskim
pubmed-article:15683753lifeskim:mentionsumls-concept:C0599861lld:lifeskim
pubmed-article:15683753pubmed:issue4lld:pubmed
pubmed-article:15683753pubmed:dateCreated2005-2-1lld:pubmed
pubmed-article:15683753pubmed:abstractTextNeurocognitive deficits are recognized as a cardinal feature of schizophrenia. Atypical antipsychotics have high affinity for many neurotransmitter receptors. Among these receptors, antipsychotics are antagonists of adrenoceptors, and this pharmacological property has been postulated to be involved in the mechanism of action of antipsychotics. We tested the hypotheses that clinical response and cognitive improvement to antipsychotic treatment are associated with genetic variation in adrenergic alpha2C receptor (ADRA2C). Fifty-seven patients with chronic schizophrenia were prospectively assessed for clinical response to antipsychotic treatment. They were subsequently genotyped for a 21 bp insertion/deletion that we identified in the 3' untranslated region (3'UTR) of ADRA2C. With regard to clinical response and cognitive improvement to antipsychotics, there was no significant association observed for this polymorphism. Our results suggest that the novel polymorphism may not play a major role in antipsychotic response.lld:pubmed
pubmed-article:15683753pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15683753pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15683753pubmed:languageenglld:pubmed
pubmed-article:15683753pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15683753pubmed:citationSubsetIMlld:pubmed
pubmed-article:15683753pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15683753pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15683753pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15683753pubmed:statusMEDLINElld:pubmed
pubmed-article:15683753pubmed:monthAprlld:pubmed
pubmed-article:15683753pubmed:issn1043-6618lld:pubmed
pubmed-article:15683753pubmed:authorpubmed-author:FaganP JPJlld:pubmed
pubmed-article:15683753pubmed:authorpubmed-author:LiebermanJeff...lld:pubmed
pubmed-article:15683753pubmed:authorpubmed-author:McEvoyJoseph...lld:pubmed
pubmed-article:15683753pubmed:authorpubmed-author:KennedyJames...lld:pubmed
pubmed-article:15683753pubmed:authorpubmed-author:MüllerDaniel...lld:pubmed
pubmed-article:15683753pubmed:authorpubmed-author:VolavkaJanJlld:pubmed
pubmed-article:15683753pubmed:authorpubmed-author:CzoborPalPlld:pubmed
pubmed-article:15683753pubmed:authorpubmed-author:LindenmayerJe...lld:pubmed
pubmed-article:15683753pubmed:authorpubmed-author:CitromeLeslie...lld:pubmed
pubmed-article:15683753pubmed:authorpubmed-author:VincentJohn...lld:pubmed
pubmed-article:15683753pubmed:authorpubmed-author:ShinkaiTakahi...lld:pubmed
pubmed-article:15683753pubmed:authorpubmed-author:SheitmanBrian...lld:pubmed
pubmed-article:15683753pubmed:authorpubmed-author:De...lld:pubmed
pubmed-article:15683753pubmed:issnTypePrintlld:pubmed
pubmed-article:15683753pubmed:volume51lld:pubmed
pubmed-article:15683753pubmed:ownerNLMlld:pubmed
pubmed-article:15683753pubmed:authorsCompleteYlld:pubmed
pubmed-article:15683753pubmed:pagination381-4lld:pubmed
pubmed-article:15683753pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:15683753pubmed:meshHeadingpubmed-meshheading:15683753...lld:pubmed
pubmed-article:15683753pubmed:meshHeadingpubmed-meshheading:15683753...lld:pubmed
pubmed-article:15683753pubmed:meshHeadingpubmed-meshheading:15683753...lld:pubmed
pubmed-article:15683753pubmed:meshHeadingpubmed-meshheading:15683753...lld:pubmed
pubmed-article:15683753pubmed:meshHeadingpubmed-meshheading:15683753...lld:pubmed
pubmed-article:15683753pubmed:meshHeadingpubmed-meshheading:15683753...lld:pubmed
pubmed-article:15683753pubmed:meshHeadingpubmed-meshheading:15683753...lld:pubmed
pubmed-article:15683753pubmed:meshHeadingpubmed-meshheading:15683753...lld:pubmed
pubmed-article:15683753pubmed:meshHeadingpubmed-meshheading:15683753...lld:pubmed
pubmed-article:15683753pubmed:meshHeadingpubmed-meshheading:15683753...lld:pubmed
pubmed-article:15683753pubmed:meshHeadingpubmed-meshheading:15683753...lld:pubmed
pubmed-article:15683753pubmed:meshHeadingpubmed-meshheading:15683753...lld:pubmed
pubmed-article:15683753pubmed:year2005lld:pubmed
pubmed-article:15683753pubmed:articleTitleIdentification of a naturally occurring 21 bp deletion in alpha 2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment.lld:pubmed
pubmed-article:15683753pubmed:affiliationNeurogenetics Section, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, 250 College Street R-30, Toronto, Ont., Canada M5T 1R8. vincenzo_deluca@camh.netlld:pubmed
pubmed-article:15683753pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15683753pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:15683753pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:15683753pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:15683753pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:15683753pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:15683753pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
entrez-gene:152entrezgene:pubmedpubmed-article:15683753lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:15683753lld:entrezgene